Get the Stockscreener App
15.35
0.92%
0.1333
Keros Therapeutics Inc stock is traded at $15.35, with a volume of 160.93K.
It is up +0.92% in the last 24 hours and down -3.64% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$15.22
Open:
$15.1
24h Volume:
160.93K
Relative Volume:
0.25
Market Cap:
$623.85M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.9928
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
+1.19%
1M Performance:
-3.64%
6M Performance:
+4.85%
1Y Performance:
-74.38%
1-Day Range:
$15.10
$15.48
1-Week Range:
$14.86
$15.48
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.36 | 463.69M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.43 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.39 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.27 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.73 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.48 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Will Keros Therapeutics Inc. price bounce be sustainableAnalyst Downgrade & Expert Curated Trade Ideas - newser.com
Is Keros Therapeutics Inc. stock reversal real or fake2025 Top Decliners & Community Verified Trade Alerts - newser.com
Will Keros Therapeutics Inc. stock return to pre crisis levelsWeekly Investment Summary & High Conviction Buy Zone Alerts - newser.com
Evaluating Keros Therapeutics Inc. with trendline analysisTrade Risk Report & Target Return Focused Stock Picks - newser.com
Published on: 2025-11-03 06:15:55 - newser.com
Why Keros Therapeutics Inc. stock remains undervalued2025 Price Action Summary & Weekly Market Pulse Alerts - newser.com
Can volume confirm reversal in Keros Therapeutics Inc.2025 Historical Comparison & Reliable Price Breakout Signals - newser.com
Will a bounce in Keros Therapeutics Inc. offer an exitJuly 2025 PostEarnings & Detailed Earnings Play Strategies - newser.com
Y Intercept Hong Kong Ltd Invests $1.40 Million in Keros Therapeutics, Inc. $KROS - MarketBeat
How to recover losses in Keros Therapeutics Inc. stock2025 Winners & Losers & High Accuracy Trade Alerts - newser.com
Reversal indicators forming on Keros Therapeutics Inc. stockJuly 2025 Sentiment & Expert Verified Movement Alerts - newser.com
What hedge fund activity signals for Keros Therapeutics Inc. stockMarket Volume Report & Verified Trade Idea Suggestions - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.Bull Run & Daily Risk Controlled Trade Plans - newser.com
How to manage a losing position in Keros Therapeutics Inc.Product Launch & Safe Entry Zone Tips - newser.com
Will Keros Therapeutics Inc. stock rally after Fed decisionsJuly 2025 Intraday Action & Safe Entry Point Alerts - newser.com
Published on: 2025-11-02 04:38:21 - newser.com
How interest rate cuts could boost Keros Therapeutics Inc. stockRate Hike & Breakout Confirmation Alerts - newser.com
Will Keros Therapeutics Inc. stock deliver consistent dividendsPortfolio Profit Report & Low Risk Profit Maximizing Plans - newser.com
Published on: 2025-11-01 09:22:31 - newser.com
Is Keros Therapeutics Inc. stock resilient to inflationQuarterly Growth Report & AI Forecast Swing Trade Picks - newser.com
Keros Therapeutics Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Keros Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges - Markets Mojo
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - MarketBeat
Is Keros Therapeutics Inc. stock attractive for income investorsJuly 2025 Closing Moves & High Accuracy Trade Alerts - newser.com
Keros Therapeutics Stock Fell 6.4% in a Month, What Now? - Trefis
How Keros Therapeutics Inc. stock reacts to bond yieldsPortfolio Profit Report & Daily Entry Point Trade Alerts - fcp.pa.gov.br
Published on: 2025-10-28 02:25:47 - newser.com
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):